Therapeutic inhibition of excessive lung inflammation induced by anti-SARS-CoV-2 antibodies

In critically ill COVID-19 patients, pneumonia is accompanied by very strong inflammatory responses, which can lead to multiple organ failure and ultimately death. The current treatment options for seriously ill COVID-19 patients are unfortunately limited. Because the development and distribution of a vaccine will take one to two years, there is an urgent need for a treatment for this category of sickest patients. Research and expected outcomes This study will investigate the underlying reason for these serious inflammatory reactions and will test which possible treatment options (medications) can counteract these extreme inflammatory reactions. The findings indicate that critically ill COVID-19 patients produce a different type of antibodies against the virus, which then causes the extreme inflammatory response. This could explain why this group of patients deteriorates so much after about a week and a half. The first results The results of the research were published in the scientific journal Science Translational Medicine on May 11, 2021. More information about the results can be found in the article by Amsterdam UMC or watch the video .